Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study

Authors:	Emilie Bernichon Claire Tissot Sophie Bayle-Bleuez Romain Rivoirard Wafa Bouleftour Fabien Forest Fabien Tinquaut Benoite Mery Pierre Fournel

Affiliation:	1. Institut de cancérologie Lucien-Newirth, Department of Medical Oncology, 108, bis avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France;2. CHU de Saint-Étienne, Pneumology department, Saint-Étienne, France;3. CHU de Saint-Étienne, Anatomo-pathology department, Saint-Étienne, France;1. Institut Gustave-Roussy, Sorbonne Université, service d’oncologie digestive, 94800 Villejuif, France;2. Centre hospitalier universitaire de Rennes, centre Eugène-Marquis, service d’oncologie digestive, 35000 Rennes, France;1. AP–HP, Sorbonne université, Saint-Antoine hospital, medical oncology department, 75012 Paris, France;2. Sorbonne université, faculté de médecine, 75020 Paris, France;3. AP–HP, Sorbonne université, hôpital Tenon, department of radiation oncology, Paris, France;4. AP–HP, Sorbonne université, hôpital Pitié-Salpêtrière, department of pneumology, 75013 Paris, France;5. AP–HP, Sorbonne université, hôpital Tenon, department of internal medicine, Paris, France;1. Centre Léon-Bérard, département de chirurgie, 28, rue Laennec, 69008 Lyon, France;2. Institut Curie, centre oncologique SIREDO (soins, innovation, recherche en oncologie de l’enfant, de l’adolescent et de l’adulte jeune), Unité AJA, 26, rue d’Ulm, 75005 Paris, France;3. Centre hospitalier universitaire de Nantes, hôpital d’Enfants, service de chirurgie pédiatrique, 7, quai Moncousu, 44093 Nantes cedex, France;4. Hôpital Necker-Enfants malades, service de chirurgie orthopédique, 149-161, rue de Sèvres, 75743 Paris cedex 15, France;5. Institut Gustave-Roussy, département de pédiatrie, 114, rue Édouard-Vaillant, 94800 Villejuif, France;1. Institut Paoli-Calmettes, département d’oncologie–radiothérapie, 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 09, France;2. CRCM (centre de recherche en cancérologie de Marseille), 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 09, France;3. Institut Paoli-Calmettes, département de physique médicale, 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 09, France;1. CHU de Nantes, oncologie pédiatrique, oncoped-PL, Nantes, France;2. Oncomip CHU, réseau régional d’onco-Occitanie, Toulouse, France;3. IUCT-oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France;4. Onco Pays de la Loire, Nantes, France;1. Centre hospitalo-universitaire de Poitiers, département d’oncologie médicale, 86021 Poitiers, France;2. Gustave-Roussy, département de médecine oncologie, Villejuif, France

Abstract:	ObjectivesImmunotherapy is the current treatment in non-small cell lung cancer (NSCLC). 20% of patients treated with immunotherapy have a prolonged response. What about the remaining 80%? How can we explain that some patients get no benefit from immunotherapy?Materiel and methodsWe retrospectively analyzed predictive factors of primary or secondary resistance to immunotherapy in NSCLC patients from 2 French hospitals between 2015 and 2018. Moreover, we evaluated whether PD1 inhibitor had an impact on the antitumor effects of salvage chemotherapy administered after immunotherapy. We chose to focus on taxanes.ResultsNinety-six patients were included in this cohort, 65(68%) patients were considered as having primary resistance and 31(32%) secondary resistance. Resistant populations did not differ. At immunotherapy initiation, median survival was 4.6 months for primary resistant patients (95%CI–4.6-6.8) and 15.6 months (95%CI–9.8-NA) for secondary resistant patients. The disease control rates with taxane were 15% in pre immunotherapy conditions vs 50% in post immunotherapy. Response rates improved regardless of the status of resistance.ConclusionThis study enriches data about immunotherapy in real-life in NSCLC. Prognostic resistance factors still seem complicated to identify. The high rate of taxane responders in post immunotherapy in this retrospective cohort support the use of taxane in therapeutic escape.

Keywords:	Non-small cell lung cancer Immunotherapy Chemotherapy Resistance Checkpoint inhibitor Response rate
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏